We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Shares of BridgeBio Pharma have gone up 60% so far in December, as the clinical-stage biopharmaceutical company focused on developing medicines for genetic diseases gears up for some important events in the months ahead, reported Markets Insider.